Investigational drug · Phase 3
KLU156
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uncomplicated Plasmodium Falciparum Malaria.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
4
Any phase or sponsor naming "KLU156"
First trial start
2024
Jan 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KLU156", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uncomplicated Plasmodium Falciparum Malaria
Approved drugs for the same conditions: Malaria · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "KLU156" as an intervention, largest first.
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum MalariaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05842954 · 1,720 participants · Start Mar 7, 2024 · Primary completion Jun 27, 2025
Drug: KLU156; Coartem · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Bobo-Dioulasso, Burkina Faso; Nanoro, Burkina Faso · 32 sites in all
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05750628 · 327 participants (planned) · Start Jan 23, 2024 · Primary completion Jun 9, 2026
Drug: INE963; KAE609 (Cipargamin) and 2 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 12 sites in all
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07811908 · 120 participants (planned) · Start Feb 12, 2026 · Primary completion Feb 4, 2027
Drug: KAE609; SoC (Coartem) and 1 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07235033 · 60 participants · Start Jan 23, 2024 · Primary completion Mar 5, 2025
Drug: KAE609; SoC (Coartem) and 1 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Abidjan, Côte d’Ivoire; Libreville, Gabon; Ahero, Kenya
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Uncomplicated Plasmodium Falciparum Malaria
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.